LRRK2 | Decrease LRRK2 kinase activity | Denali—DNL-151 | Phase 1 | NCT04056689 |
Denali—DNL-201 | Phase 1 | NCT03710707 |
Glucocerebrosidase | Chemical chaperone to translocate mutant enzyme from the endoplasmic reticulum into lysosomes | Ambroxol | Phase 2 | NCT02941822 and NCT02914366 |
Allergan—LTI-291 | Phase 1 | Netherlands Trial NL7061 |
Block accumulation of the glucocerebrosidase substrate, glucosylceramide | Genzyme/Sanofi—Ibiglustat (GZ/SAR40267) | Phase 2 | NCT02906020 |
α-Synuclein | Anti–α-synuclein monoclonal antibodies to lower α-synuclein concentrations and block cell-to-cell transmission | Biogen—Cinpanemab | Phase 1/2 | NCT03318523 and NCT03716570 |
Hoffmann–La Roche/Prothena— Prasinezumab | Phase 2 | NCT03100149 |
Abbvie—ABBV 0805 | Phase 1 | NCT04127695 |
Takeda/AstraZeneca—MEDI1341 | Phase 1 | NCT03272165 |
Lundbeck—Lu-AF-82422 | Phase 1 | NCT03611569 |
Inhibitors of pathological α-synuclein aggregation | Enterin—ENT-01 | Phase 1 | NCT03938922 |
Alterity Therapeutic— PBT434 | Phase 1 | U1111–1211-0052 |
Neuropore Therapies Inc./UCB S.A.—NPT200-11 | Phase 1 | NCT02606682 |
c-Abl kinase | c-Abl kinase inhibition | SPARC—K0706 | Phase 2 | NCT03655236 |
Novartis—Nilotinib | Phase 2 | NCT02954978 and NCT03205488 |
1ST Biotherapeutics, Inc—FB-101 | Phase 1 | NCT04165837 |
GLP-1 receptor | GLP-1 receptor agonist, decreases inflammation | Amylin Pharmaceutical/ AstraZeneca—Exenatide | Phase 3 | NCT03456687, NCT04154072, and ISRCTN14552789 |
Novo Nordisk—Liraglutide | Phase 2 | NCT02953665 |
Sanofi—Lixisenatide | Phase 2 | NCT03439943 |
Neuraly—NLY01 | Phase 2 | NCT04154072 |